News & Updates

A red magnifying glass.

Concomitant azole use may influence bleeding risk in AF patients on NOACs

Concomitant azole use may influence bleeding risk in AF patients on NOACs

In a study evaluating azole use in patients with atrial fibrillation (AF) on non-vitamin K antagonist oral anticoagulants (NOACs), systemic exposure to the antifungal agent fluconazole was associated with an elevated risk of bleeding, particularly among those on apixaban. Conversely, no association was seen between NOACs and topical azoles*.

Concomitant azole use may influence bleeding risk in AF patients on NOACs

Three layers of stigma prevent mental health recovery in Singapore

Three layers of stigma prevent mental health recovery in Singapore

Internalized stigma, compounded by public, structural, and systemic stigmas pose substantial barriers to recovery among persons with mental illnesses (PMI), according to a recent Singapore study.

Three layers of stigma prevent mental health recovery in Singapore

Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD

Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD

Olaparib demonstrates clinical activity across patients with platinum-sensitive relapsed ovarian cancer and known BRCA mutation and homologous recombination deficiency (HRD), as shown in the phase II LIGHT study.

Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD

15 Jul 2022

Genes for elevated blood pressure contribute to pre-eclampsia risk

Genes for elevated blood pressure contribute to pre-eclampsia risk

Genetic predisposition to high blood pressure appears to heighten the risks of pre-eclampsia, recurrent pre-eclampsia, and pre-eclampsia with severe features, a study has found.

Genes for elevated blood pressure contribute to pre-eclampsia risk

Abrocitinib: The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis

Abrocitinib: The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis

Abrocitinib, the first janus kinase (JAK)1 inhibitor specifically indicated for the treatment of moderate-to-severe atopic dermatitis (AD), was recently approved in Singapore. During a webinar hosted by the Dermatological Society of Singapore, with the support of Pfizer, Professor Stephan Weidinger of University Hospital Scheswig-Holstein, Germany discussed several cases that exemplified appropriate patient selection for this novel agent.

Abrocitinib: The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population

14 Jul 2022

Healthy sleep cuts frailty risk in older adults

Healthy sleep cuts frailty risk in older adults

Having good sleep health across multiple dimensions appears to reduce the risk of frailty among older adults, reports a recent Taiwan study.

Healthy sleep cuts frailty risk in older adults

Thermoelectric warming therapy beneficial in MGD-related dry eye disease

Thermoelectric warming therapy beneficial in MGD-related dry eye disease

A device that applies consistent emissive heat to the meibomian glandular apparatus appears to produce significant improvements in the signs and symptoms of dry eye disease in patients with meibomian gland dysfunction (MGD), with the benefits sustained over 6 months following treatment initiation, as shown in a study.

Thermoelectric warming therapy beneficial in MGD-related dry eye disease

14 Jul 2022

Aspirin use lowers risk of liver cancer

Aspirin use lowers risk of liver cancer

A recent study has shown that use of aspirin can help reduce the risk of developing liver cancer.

Aspirin use lowers risk of liver cancer

PSA testing helps prevent prostate cancer deaths

PSA testing helps prevent prostate cancer deaths

A prostate specific antigen (PSA)-based screening is effective in significantly lowering the risk of death from prostate cancer (PC), reports a study. However, nonattendance, initiation after age 60 years, and discontinuation at age 70 years appear to increase such risk.

PSA testing helps prevent prostate cancer deaths

14 Jul 2022

Something went wrong.